186 related articles for article (PubMed ID: 2039192)
1. Activity of temafloxacin against respiratory pathogens.
Swanson RN; Hardy DJ; Chu DT; Shipkowitz NL; Clement JJ
Antimicrob Agents Chemother; 1991 Mar; 35(3):423-9. PubMed ID: 2039192
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of temafloxacin against gram-negative bacteria: an overview.
Hardy DJ
Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890
[TBL] [Abstract][Full Text] [Related]
3. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
Azoulay-Dupuis E; Bedos JP; Vallée E; Hardy DJ; Swanson RN; Pocidalo JJ
J Infect Dis; 1991 Feb; 163(2):319-24. PubMed ID: 1988515
[TBL] [Abstract][Full Text] [Related]
4. Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.
Arai S; Gohara Y; Akashi A; Kuwano K; Nishimoto M; Yano T; Oizumi K; Takeda K; Yamaguchi T
Antimicrob Agents Chemother; 1993 Feb; 37(2):287-92. PubMed ID: 8383942
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K
Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
Bongaerts GP; Hoogkamp-Korstanje JA
Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
[TBL] [Abstract][Full Text] [Related]
8. Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens.
Hardy DJ
Am J Med; 1991 Dec; 91(6A):12S-14S. PubMed ID: 1662881
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the bactericidal activity of temafloxacin.
Jacobs MR
Am J Med; 1991 Dec; 91(6A):31S-34S. PubMed ID: 1662893
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Ozaki M; Matsuda M; Tomii Y; Kimura K; Segawa J; Kitano M; Kise M; Shibata K; Otsuki M; Nishino T
Antimicrob Agents Chemother; 1991 Dec; 35(12):2496-9. PubMed ID: 1667252
[TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of temafloxacin for gram-positive pathogens.
Bille J; Glauser MP
J Antimicrob Chemother; 1991 Dec; 28 Suppl C():9-14. PubMed ID: 1664835
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
13. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.
Hardy DJ; Swanson RN; Hensey DM; Ramer NR; Bower RR; Hanson CW; Chu DT; Fernandes PB
Antimicrob Agents Chemother; 1987 Nov; 31(11):1768-74. PubMed ID: 3435123
[TBL] [Abstract][Full Text] [Related]
14. Temafloxacin: in vitro comparison with five other antibacterial agents.
Digranes A; Hardardottir H; Bottolfsen KL
Chemotherapy; 1991; 37(2):98-105. PubMed ID: 2032475
[TBL] [Abstract][Full Text] [Related]
15. The in-vitro activity of temafloxacin, against gram-positive bacteria.
Mandell LA; Lawrence T; Rotstein C; Gorzynski EA; Beam TR; Amsterdam D
J Antimicrob Chemother; 1991 Dec; 28 Suppl C():15-24. PubMed ID: 1664826
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro activity of temafloxacin compared with other antimicrobial agents.
King A; Bethune L; Phillips I
J Antimicrob Chemother; 1991 Jun; 27(6):769-79. PubMed ID: 1657855
[TBL] [Abstract][Full Text] [Related]
17. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
Pechère JC; Gootz TD
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections.
Wakebe H; Imada T; Yoneda H; Mukai F; Ohguro K; Ohmori K; Tamaoka H; Yabuuchi Y
Antimicrob Agents Chemother; 1994 Oct; 38(10):2340-5. PubMed ID: 7840567
[TBL] [Abstract][Full Text] [Related]
19. The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin.
Nye K; Shi YG; Andrews JM; Ashby JP; Wise R
J Antimicrob Chemother; 1989 Sep; 24(3):415-24. PubMed ID: 2808194
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus.
Fuchs PC
Am J Med; 1991 Dec; 91(6A):15S-18S. PubMed ID: 1662886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
